SageView Advisory Group’s Matinas BioPharma MTNB Stock Holding History

SageView Advisory Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$6	–	1754
2025 Q4	$6	Buy	+1	New	+$18	﹤0.01%	2599

Other funds holding MTNB

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SageView Advisory Group's MTNB Position: Q1 2026 in Review

SageView Advisory Group sold out of Matinas BioPharma (MTNB) in Q1 2026, closing a stake of 1 share — an estimated $6 sold.

SageView Advisory Group first reported a position in MTNB in Q4 2025 and held it in 1 quarter. The position peaked at $6 in Q4 2025. 24 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.

SageView Advisory Group reported no remaining Matinas BioPharma position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 1 Matinas BioPharma share in Q1 2026, an estimated $6.
SageView Advisory Group first reported a position in Matinas BioPharma in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Matinas BioPharma position peaked at $6 in Q4 2025.
24 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.